The Boston-based venture capital firm Vida Ventures snagged $600 million more to invest in early-stage biotech companies in a second fund, it announced Thursday.
That fund should bolster the firm’s attempts to become a more significant player in the cottage industry of biotech venture capitalists. Vida has only formally invested in 14 companies since its launch in April 2018, though one — the cell therapy company Allogene (ALLO)— has already gone public. Merck bought another, Peloton Therapeutics, for $1 billion upfront.
About the Author Reprints
